Current opinion in ophthalmology
-
Curr Opin Ophthalmol · May 2011
Review Comparative StudyRanibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
This paper reviews the recent literature regarding the effectiveness, efficacy and safety of intravitreal bevacizumab as compared with ranibizumab for the treatment of neovascular age-related macular degeneration (nAMD). ⋯ Numerous clinical trials, including the Comparison of AMD Treatment Trial, are underway examining the comparative efficacy of ranibizumab versus bevacizumab for the treatment of nAMD. While these studies may demonstrate clinical noninferiority of one anti-VEGF compound over another, they may not be adequately powered to detect important differences in ocular and systemic safety. Large-scale, appropriately powered safety studies need to be conducted to evaluate differences in safety.
-
Treatment for diabetic macular edema (DME) is continuously evolving. While focal laser photocoagulation remains the standard of care, a new wave of studies is emerging that shows benefit of adjunctive therapy for DME. ⋯ The goal of this article is to briefly summarize recent data from these trials, in order to aid the clinician in evaluating the most appropriate and up-to-date nonsurgical management options in treating diabetic macular edema. The key points are to summarize the most recent peer-reviewed literature regarding therapy for diabetic macular edema. Particular attention is paid to focal laser, corticosteroid, and anti-VEGF therapies.